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Abstract
Cognitive-behavioral therapy (CBT) is currently the “gold standard” for treatment of bulimia
nervosa (BN), and is effective for approximately 40–60% of individuals receiving treatment;
however, the majority of individuals in need of care do not have access to CBT. New strategies for
service delivery of CBT and for maximizing maintenance of treatment benefits are critical for
improving our ability to treat BN. This clinical trial is comparing an Internet-based version of
CBT (CBT4BN) in which group intervention is conducted via therapeutic chat group with
traditional group CBT (CBTF2F) for BN conducted via face-to-face therapy group. The purpose
of the trial is to determine whether manualized CBT delivered via the Internet is not inferior to the
gold standard of manualized group CBT. In this two-site randomized controlled trial, powered for
non-inferiority analyses, 180 individuals with BN are being randomized to either CBT4BN or
CBTF2F. We hypothesize that CBT4BN will not be inferior to CBTF2F and that participants will
value the convenience of an online intervention. If not inferior, CBT4BN may be a cost-effective
approach to service delivery for individuals requiring treatment for BN.
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BN is a serious psychiatric disorder that occurs in approximately 1.5% of women and 0.5%
of men and typically onsets in adolescence or early adulthood [1]. Cognitive-behavioral
therapy (CBT) is the evidence-based treatment of choice for bulimia nervosa (BN), yet a
considerable porportion of patients with BN do not have access to this approach. By
leveraging technology and Internet-based delivery, we are exploring whether an Internet-
based version of CBT (CBT4BN) in which group intervention is conducted via moderated
therapeutic chat group is not inferior to the gold standard of face-to-face group CBT for BN
(CBTF2F). This trial represents a shift in emphasis from improving efficacy of treatments to
improvement of service delivery. Existing services are sub-optimal because: (1) even the
best available treatment (CBT) does not help all patients, and (2) not all patients have access
to CBT. Therefore, extending the reach of treatment to a greater number of individuals with
a treatment that is not inferior to the gold standard is a reasonable strategy to address patient
access—especially, if achievable in a cost-efficient manner.
1.1 Significance of Bulimia Nervosa
The core features of BN include repeated episodes of binge eating followed by inappropriate
use of compensatory behaviors such as self-induced vomiting or misuse of laxatives.
Individuals with BN place undue emphasis on body weight and shape on their self-
evaluation [2]. BN is associated with significant medical and psychiatric morbidity [3].
Specifically, individuals with BN frequently present with major depression and anxiety
disorders, display problems with impulse control, and are at increased risk for substance use
disorders and Axis II pathology [4–11].
Physical complications of BN include fatigue, gastrointestinal problems, reflux, esophageal
tears, electrolyte imbalances, and cardiac irregularities [12–14]. Mortality from BN is
elevated [15]. Although one-half to two-thirds of individuals with BN eventually achieve
full or partial remission [12, 16, 17], 23% of cases have a protracted course [18]. In addition,
crossover to eating disorder not otherwise specified (EDNOS) and binge eating disorder
(BED) occurs in nearly 20% of cases [18]. Thus, BN is frequently associated with
significant long-term medical and psychological impairment.
1.2 Treatment for Bulimia Nervosa: Examining the Evidence Base
CBT is a multi-modal intervention that includes psychoeducation, self-monitoring,
recognizing and modifying responses to antecedent cues, challenging automatic thoughts,
thought restructuring, problem solving, exposure with response prevention, and relapse
prevention [19–21]. CBT is currently considered the “gold standard” for treatment of BN in
adults [22–24]. Approximately 40–60% of patients who complete CBT treatment
demonstrate significant improvement [21, 25–30].
Notably, group and individual CBT for BN are effective [31–33]. Individuals in both
treatments demonstrate decreases in objective and subjective binge episodes, vomiting,
laxative use, and and cognitive and behavioral features of the eating disorder [31, 33]. Given
the similarity of outcomes, group CBT is more economical from a cost-effectiveness
perspective and represents a more parsimonious use of the therapist’s time [34].
There are two significant issues limiting the effectiveness of CBT in the treatment of BN. A
significant minority of individuals do not respond to intervention and rates of attrition are
high [24]. Moreover, relapse following treatment remains a substantial concern. Outcome
studies suggest one third of women relapse [16] and that six months post treatment
represents the highest risk period for relapse [35] with risk declining four years after
treatment [16].
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Second, although CBT is effective for a substantial portion of individuals seeking treatment,
it is unavailable to many [36]. Well-trained CBT therapists are not available in many
locations in the United States and throughout the world and telemedicine options are just
emerging [37–39]. Thus many individuals requiring care are unable to access CBT, or
accessing treatment is burdensome secondary to time or financial commitments. Group
formats for CBT can also deter those with considerable social anxiety. To address this
problem, the creation of new service delivery approaches are important [40, 41].
1.3 Incorporating Technology is Essential
Incorporating technology into CBT represents an attractive option to enhance mental health
care for patients with BN. The Internet is rapidly becoming the primary source of healthcare
information [42] and consumers are increasingly also turning to the Internet and other forms
of technology for treatment, coaching, and support [43–45]. Modern Internet-based
interventions are enhanced by interactive websites, self-monitoring and feedback tools and
communication platforms [46].
Successful computer-based programs and the use of online anonymous environments have
been reported for a number of problems including obsessive compulsive disorder, sexual
abuse, anxiety, depression, obesity, smoking, and eating disorders [47–55]. One variable
feature of computer-aided psychotherapy is the extent to which, and frequency with which,
interaction with a human being occurs [56]. It seems to be important that at least short and
regular therapeutic contact is provided, otherwise high drop-out rates and reduced
effectiveness are likely to occur [57]. To integrate a group therapy setting in a web
application, text-based chat-groups have been shown to be an appropriate tool [58]. For
example Golkaramnay [59] investigated the effectiveness of group therapy delivered via
Internet chat following inpatient treatment in 114 patients with various psychiatric diagnoses
versus a matched control (no chat) group. Chat groups met weekly for 12–15 weeks for 90
minutes. Results showed that chat was well accepted as evidenced by a low dropout rate
(9.4%), high session attendance (85%), and positive evaluation of sessions (90% were
satisfied). Twelve months after discharge, chat participants showed a substantially lower risk
for negative outcome relative to controls (24.7% versus 38.5%) and significantly fewer chat
participants (22.2%) than control participants (46.5%) experienced a relapse [60]. Thus,
chat-based therapy is an attractive platform for disseminating evidence-based treatment for
psychiatric disorders.
2. Objectives of the Clinical Trial
The overall objective of this trial is to determine whether CBT4BN yields outcomes that are
not inferior to those obtained with CBTF2F as a crtical first step in informing enhancements
to health service delivery for patients with BN. In this manuscript, we detail the design and
methods of the clinical trial and introduce the nature of the chat therapy delivery method.
The study has four specific aims: To (1) compare the relative efficacy of CBT4BN versus
CBTF2F; (2) determine the relative attrition, adherence, and acceptability of CBT4BN
versus CBTF2F; (3) compare maintenance of treatment gains between CBT4BN versus
CBTF2F; and (4) determine the relative cost-effectiveness of CBT4BN versus CBTF2F.
3. Study Design
3.1 Overview
The study is being conducted at University of North Carolina at Chapel Hill and at Western
Psychiatric Institute and Clinic (WPIC) of the University of Pittsburgh Medical Center.
Participants are being recruited from the greater Raleigh-Durham and Pittsburgh
metropolitan areas. Participants are randomly assigned (using a permuted block algorithm
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stratified by center) to 16 sessions over 20 weeks of either CBT4BN or CBTF2F (12 weekly
sessions followed by 4 fortnightly sessions). Follow-up evaluations are scheduled at three,
six, and 12 months post-treatment. The governing Institutional Review Board (IRB) at the
University of North Carolina at Chapel Hill and the University of Pittsburgh Medical Center
approved the protocol for this study.
3.4 Inclusion/Exclusion Criteria
Inclusion—To be eligible for participation, individuals must: (1) meet criteria for DSM-IV
BN; (2) be age 18 or older; (3) speak English; and (4) have reliable, private Internet access.
Participants in this study are permitted to take medications including psychotropic
medications but are asked to not modify medications or dosages during the duration of the
clinical trial.
Exclusion—Participants are excluded from the study if they report any of the following:
(1) any major medical condition that would interfere with treatment or require alternative
treatment (e.g., type 1 diabetes mellitus); (2) alcohol or drug dependence in the last three
months; (3) current significant suicidal ideation reported during the clinical assessment or on
the Beck Depression Inventory-II (BDI–II) [61] at baseline; (4) developmental disability that
would impair the ability of the participant to benefit from psychotherapy or to use the
Internet program effectively; (5) psychosis, including schizophrenia, and (6) bipolar I
disorder.
3.3 Recruitment, Retention, and Incentives
Participants are recruited from the Eating Disorders Program at the University of North
Carolina and the Center for Overcoming Problem Eating at the University of Pittsburgh to
achieve a final sample size of 180. In addition, we send regular letters to local university
counseling centers, physicians, and mental health organizations, particularly those that serve
minority groups. Advertisements are also placed in local media through university Listservs,
and radio advertisements and in social media through Facebook and Twitter.
We implement several strategies to minimize attrition, including the use of incentives.
Participants are given $20 for completing the end of treatment assessment and $20 for
completing the 12 month post-treatment assessment. Additional measures used to minimize
attrition include asking participants to provide at least two phone numbers or email
addresses where they can be reached and asking for an alternative or emergency contact who
would know their contact information. Reminder calls and/or emails are made for all
assessment appointments. At least six attempts are made (at several times of day and night)
to reschedule missed assessment appointments. The number of sessions attended by
participants are also being recorded and will be considered in the analyses.
3.4 Assessment Schedule
Table 1 presents the assessment schedule for the clinical trial. Individuals in CBT4BN




Eating Disorders Examination (EDE; [62]): The EDE is a valid and reliable investigator-
administered interview used to assess current eating disorder symptoms and is used as the
primary measure of treatment outcome.
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Eating Disorders Examination—Questionnaire Version (EDE-Q; [63]): The EDE-Q is a
38-item self-report measure based on the EDE. It requires about 15 minutes to complete.
Research suggests good agreement between the EDE and EDE-Q on objective bulimic
episodes, dietary restraint, and the attitudinal features of shape and weight concerns [64, 65].
The EDE-Q assesses interim changes in eating disorders symptoms during the acute and
follow-up periods.
The Short Evaluation of Eating Disorders (SEED; [66]) is a brief instrument designed to
assess eating disorder symptoms on a weekly basis during treatment participation.
ADQ: The ADQ is a follow-up to the SEED which asks participants to record the exact
number of times and days per week they engaged in eating disorder behaviors [66].
Height and Weight: We weigh patients according to protocol at baseline using a regularly
calibrated digital scale. Self-reported weights are acceptable if participants are unable or
unwilling to return for face-to-face follow-up assessments. We measure height at baseline
using a stadiometer.
Pregnancy Questionnaire: Because weight changes are an outcome variable, we include a
7-item self-report questionnaire assessing current pregnancy, any previous post-treatment
pregnancies, birth and lactation status, and pre-pregnancy weight.
McKnight Follow-up of Eating Disorders (MFED): The MFED, developed for the
McKnight Foundation studies [40, 67–71] provides interim measures of eating disorder
status, status of comorbid psychopathology, and additional treatment received including
other medical utilization. The instrument was developed from the Longitudinal Interval
Follow-Up Evaluation (LIFE) [72] with additional questions adapted from the Structured
Clinical Interview for DSM-IV (SCID), and specific questions developed for measuring
medical and mental health utilization. In this trial, we employ only the utilization portion (as
eating disorder outcome is being measured in other ways).
Comorbid Psychopathology
Structured Clinical Interview for DSM-IV Axis I Disorders - Patient Edition (SCID-I/
P; [73]): The SCID-I/P, a well-studied and widely used semi-structured interview, assesses
comorbid Axis I disorders.
Beck Depression Inventory-II (BDI–II; [61]): The BDI, a 21-item self-report
questionnaire assesses the severity of current depressive symptoms; the revised version
extends the reporting time frame to two weeks.
Beck Anxiety Inventory (BAI; [74]): The BAI is a 21-item self-report measure of anxiety
that focuses on somatic symptoms converges with other measures of anxiety and has good
reliability and validity.
Clinical and Research Inventory for Eating Disorders (CREAT; [75]: The emotion
dysregulation subscale (8 items) of the CREAT assesses participant’s awareness of his or
her own emotional state. It serves as a supplement to the BDI.
Temperament and Character Inventory (TCI: [76]) The TCI is a 240-item self-report
measure that provides assessments of 4 temperament and 3 character dimensions. We are
particularly interested in the assessment of harm avoidance and novelty seeking—
temperamental traits that have been documented as significant in patients with BN and self-
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directedness, a character scale that has been associated with rapid and positive treatment
response in BN—and major depression [77, 78], and shown to improve with successful
treatment of BN [79]. Self-directedness is assessed at mid-treatment and in post-treatment.
Suicidal Behavior Interview: This is a brief interview (11 items) assessing lifetime self-
harm, suicide attempts, and suicidal ideation. All interviewers follow safety assessment
protocols in the event that a participant endorses suicidal or self-harm thoughts or behaviors.
Quality of Life
Short-Form Health State Classification (SF-6D; [80]): This is a brief self-report form
designed to measure quality of life in six dimensions: physical functioning, role limitation,
social functioning, bodily pain, mental health, and vitality. Derived from the commonly used
SF-36, it is briefer and has preference weightings for calculation of health utilities in cost
effectiveness analysis.
Eating Disorders Quality of Life Questionnaire (EDQOL; [81]): The EDQOL is a
health-related quality of life questionnaire that was designed specifically for use with
disordered eating patients. The 26-item instrument has excellent test-retest reliability and
convergent validity.
Web Self-Efficacy—We use a 16-item questionnaire [82], in which users evaluate their
experience with, training in, and expectations for using the Internet.
Treatment Evaluation
Treatment Acceptability: This 9-item self-report measure designed for this study assesses
participants’ preferences, expectations, and concerns about each treatment condition. It is
administered prior to beginning the active treatment phase of the study. Participants answer
questions about their expectations for both study conditions.
Post-Treatment Evaluation: This is a 24-item self-report measure designed for this study
of participants’ experiences in their assigned study treatment condition. Following active
treatment participants answer questions based on the condition that they participated in with
all questions specific to elements of either the chat or face-to-face group.
Post-Group Evaluation: This is a 15-item self-report measure designed for this study that
assesses participants’ level of comfort, whether the participants feel supported by the other
group members and therapist, and participant emotions following group. The measure also
assesses self-reported participant safety at the end of group. Patients complete this weekly at
the end of group for all participants. Group therapists are blind to all post-group ratings with
the exception of the participant safety question.
Reasons for Drop-Out: This self-report questionnaire was designed for this study and is
provided to participants who drop out of the active treatment phase. The questionnaire
queries why the group may not have been a good fit for the participant and provides space
for specific reasons for drop-out. The questionnaire is presented in a checklist format where
participants can indicate any reasons for drop out that may have applied to them.
4.0 Interventions
Individuals are randomized to receive either CBT4BN or CBTF2F. During acute treatment
(20 weeks) all individuals are asked to self-monitor in the manner consistent with CBT (e.g.,
food consumption, binge/purge episodes, situation, thoughts, feelings, intensity). Individuals
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in the CBTF2F condition complete their monitoring in self-monitoring booklets by hand and
those in CBT4BN complete their monitoring via the CBT4BN website.
4.1 Development of Treatment Manuals for CBTF2F and Internet Modules for CBT4BN
The treatment manual used in CBTF2F and from which the CBT4BN modules were built
was initially developed for use in a randomized trial designed to dismantle CBT for the
treatment of BN [83]. The basic modules of the CBT intervention include: psychoeducation,
self-monitoring, normalization of meals (especially breakfast), cue identification,
challenging automatic thoughts, thought restructuring, chaining, and relapse prevention—
with special sections on body image, assertiveness, and cultural messages regarding thinness
and appearance. Specific goals for each session are outlined clearly in the manuals and
modules and homework is assigned after each session. The treatment has been modified
both for group format delivery (CBTF2F) over 12–16 sessions and for Internet delivery via
CBT4BN and now includes two nutrition modules that focus on the exchange system and
are designed to be delivered by a registered dietitian.
Both treatments consists of sixteen, 1.5-hour long sessions delivered over a total of 20
weeks (12 weekly and 4 fortnightly sessions). Groups include 3–5 participants, one
therapist, and two sessions with a registered dietitian. The progression of topics is presented
in Table 2. Two flex sessions are included in the schedule to be used at the therapist’s
discretion. If a group struggles with a particular topic or needs additional work, the therapist
can invoke a flex session.
4.2 CBTF2F Procedures
Each week, individuals in CBTF2F complete the pre-group assessments (SEED, ADQ,
CREAT-ED) via paper and pencil. Self-monitoring is also done via pencil and paper and is
collected weekly at each session by the therapist. Each week the therapist returns previous
self-monitoring booklets with feedback to the participants and provides new blank self-
monitoring booklets. Each group begins with a review of self-monitoring and progresses
through the target topic of the week. Participants are given a copy of the module for the
following session at the end of each group. At the end of each group meeting, participants
complete post-group questionnaires via pencil and paper and turn them in to the therapist
who looks only at the safety question. If a participant indicates not feeling safe, the therapist
remains with them following group to further assess safety.
4.3 CBT4BN Procedures
The CBT4BN website was built using php, javascript and css and included separate pages
for chat group log in, questionnaire assessment (via Web-Akquasi [84, 85]), self-monitoring,
study modules and study worksheets. Participants create anonymous usernames and
passwords to ensure privacy and confidentiality.
CBT4BN is divided into independent modules for the purpose of this study. Accordingly,
individuals are only able to access the current week’s module and modules from previous
weeks. This allows investigators to equate the pattern of timing of delivery of topics across
conditions so that we can more accurately assess the impact of mode of delivery on efficacy
of CBT. The modules are released according to the same schedule as CBTF2F outlined in
Table 2. Participants are able to access the site at any time. A technical support email
address is provided so that participants can contact study coordinators for technical
problems. Self-monitoring is conducted through the website. Therapists are able to check in
on patients’ progress and provide online feedback to self-monitoring and homework
exercises at on regularly determined days throughout the week.
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Each week, participants in CBT4BN log in 10 minutes prior to chat and complete the pre-
chat assessments (SEED, ADQ, CREAT-ED). Participants are required to enter their current
phone number and their current physical address as a safety measure and are then permitted
to enter the chat room. Participants who miss a chat session receive a phone call from the
therapist. Individuals with specific or personal concerns are able to send a request for a 10-
minute private chat session with the therapist. These can be conducted after the scheduled
chat session. Chats are hosted on the website via the secure UNC Eating Disorders server
and participants all use appropriate chat pseudonyms. The chat is text-based, neither video
nor audio is included. Post-group questionnaires are completed online at the end of the chat.
If a CBT4BN participant indicates feeling unsafe on the post-group questionnaire, the
therapist and study coordinators are immediately alerted by email and the therapist follows
up with the participant by phone.
Given the novelty of the chat-based delivery format, we include a deidenfitied excerpt from
a CBT chat session in the Appendix. This excerpt is from a group session attended by the
therapist and 4 patients and occurs near the end of a course of CBT4BN. Comment boxes to
the right of the chat alert the reader to unique features of the chat such as direct participant
to participant communication, the use of emoticons to convey emotion, and the challenges of
monitoring parallel conversations. A color version of the Appendix is available at
http://insertwebsitehere.
5. Therapists, Training, and Supervision
Therapists for both conditions are Ph.D. level clinical psychologists or highly experienced
master’s level clinicians with experience in the provision of psychotherapy for eating or
weight disorders.
Training
All therapists (CBTF2F and CBT4BN) familiarize themselves with the treatment manual
and read specified preparatory material prior to initiating treatment. An initial two-day
workshop was conducted at the beginning of the study for all therapists involved. Drs. Bulik
and Marcus provided training in CBT.
Supervision
Dr. Bulik serves as the overall, study-wide supervisor for group and chat therapy as well as
the on-site supervisor in Chapel Hill. Dr. Marcus serves as the on-site supervisor in
Pittsburgh. Each supervisor meets weekly with study therapists to review patient progress as
well as therapist adherence to treatment protocols. Cross-site supervision occurs via
telephone as needed to ensure adequate supervision coverage as well as supervision
consistency. Group sessions are audiotaped and chat transcripts are electronically saved and
reviewed by Drs. Bulik and Marcus. Detailed feedback on each tape and transcript are
provided to the therapists by one or both of the study supervisors. Audiotapes for CBT
groups and chat transcripts are rated for fidelity to the treatment manual using an adaptation
of a fidelity rating scale developed to assess adherence to treatment protocol in a large
behavioral therapy outcome study [86]. Three tapes and three chat transcripts, representing
early, middle and late therapy sessions, are rated for each group. Ratings are completed by
individuals trained to criterion on each rating instrument.
6. Statistical Analyses
For the first specific aim, to compare the relative efficacy of CBT4BN versus CBTF2F, the
analysis will be a logistic regression where the predictor variable is treatment assignment,
and the response for each participant is abstinence, defined as the completion of 16 sessions
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(20 weeks) of treatment and evaluation and being abstinent at the 20-week visit.
Conservatively, we will define all participants who fail to meet criteria for abstinence as
non-abstinent, under the assumption that if a participant is not able to complete 16 sessions
of the treatment, then the treatment has failed to help the participant to achieve abstinence.
Thus, for the primary efficacy outcome, we will have no missing data. We have defined the
non-inferiority margin as 0.06, justified below under Statistical Power. We will conduct two
sensitivity analyses: 1) we will repeat the analysis on completers only, thus making dropouts
missing data; and 2) if possible, we will classify dropouts as abstainers or non-abstainers,
and then repeat the analysis for all subjects (dropouts plus completers) for whom we are able
to make this classification. For the additional primary outcome variables of binge and purge
frequency, we will use Poisson regression as these are count variables. We will perform the
same sensitivity analyses, consider possibility of a site effect, and assess potential mediators
and moderators.
For the second aim, to determine the relative attrition, adherence, and acceptability of
CBT4BN versus CBTF2F, we will focus on all-cause treatment discontinuation (dropout) at
the end of treatment. Aside from the difference in outcome variable, this hypothesis differs
from the primary outcome in that a participant who remains in the study for 20 weeks, but
fails to be abstinent would meet this hypothesis’s criterion for completion, even though she/
he would fail to meet criteria for abstinence in Aim 1. The primary analysis will be a logistic
regression, with provision for a site effect with site included as a covariate.
For the third aim, to compare maintenance of treatment gains between CBT4BN versus
CBTF2F, the analysis for these outcomes will parallel the analyses for Aim 1, namely a non-
inferiority analysis using logistic regression.
Finally, for the fourth aim, to determine the relative cost-effectiveness of CBT4BN versus
CBTF2F, we propose a cost minimization analysis based on our primary non-inferiority
hypothesis. The cost minimization or cost effectiveness (CE) will be calculated from the
third party payer perspective. In addition, a second set of CE analyses from a societal
perspective will be completed, using time associated with traveling to and from treatment, as
well as the time treatment takes up. Analyses will be conducted based on end of treatment
status.
7. Data Management and Safety Monitoring Plan
All participants have a full physical examination at the time of assessment to include height,
weight, pulse, and blood pressure. In addition, participants undergo a blood draw for
laboratory assessment of Na, K, Cl, CO2, BUN, creatinine, glucose, Ca, Mg, AST, ALT,
lipase, CBC, and a serum pregnancy test. A 12 lead EKG is also performed on each
participant at the time of baseline assessment. Laboratory assessments are repeated as often
as deemed appropriate by the physician based on clinical history.
Participants are referred to their primary care physician if necessary for ongoing medical
care during the course of the study. Weekly administration of the SEED, ADQ, and CREAT
allow for careful tracking of any deterioration in symptoms and monitoring of harms
associated with either CBTF2F or CBT4BN. CBT4BN participants have a monthly
scheduled check-in call with the study physician at their site. At follow-ups, all patients are
queried regarding any non-study interventions (psychotherapy or medications) that they
have received for the treatment of BN.
Data are double-entered by the research assistants with extensive experience in database
management. Participants are assigned a code number, which is used, instead of names, to
maintain confidentiality. Only study staff have access to identifiable information, and they
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are required to complete Health Insurance Portability and Accountability Act (HIPAA)
training. In addition, all study staff are required to complete comprehensive research ethics
training and to provide documentation prior to funding. All data are collected and
maintained in accordance with these legal and ethical standards. All data are transmitted
encrypted, the database is password-protected, regularly backed up, and maintained on a
secure server behind a firewall.
An independent Data and Safety Monitoring Board (DSMB) is responsible for monitoring
the safety of the data obtained in the proposed investigation. The DSMB meets bi-annually,
has access to all protocol data, and has the authority to inquire into protocol process and to
suspend or terminate the protocol. The board also ensures that the study is being conducted
according to protocol specifications. The DSMB receives copies of all reportable adverse
events. Any adverse events are reported to the IRB, as well as to the National Institute of
Mental Health. In accordance with the Office of Research Subjects Protection reporting
requirements, any serious, unexpected, related, or possibly related adverse events is reported
to the IRB in writing within two business days of occurrence. The DSMB also prepares
yearly reports on the study, which is included in yearly continuation applications.
8. Discussion
BN is a serious mental illness and evidence-based treatment is challenging to access for
many individuals. The results of this trial have potential to broaden our therapeutic reach
and extend availability of CBT to individuals who fdo not have ready access to CBT. Initial
anecdotal feedback indicates that patients value the convenience of being able to participate
in group therapy without the inherent hassles of travel, parking, and transportation costs.
Therapists also find the chat format engaging and value the flexibility in scheduling afforded
by an online intervention (i.e., must not be confined to work hours or office availability).
In addition to these advantages, there are also challenges inherent in the implementation of
this protocol. First, therapists are not equally comfortable with a chat-based delivery.
Individuals who are more comfortable with the chat medium may be more effective at
managing the therapeutic flow with several patients chatting simultaneously. This is not
dissimilar to therapist experiences with telemedicine delivery of CBT [87], in which
therapists conducting face-to-face treatment rated therapeutic bond more positively than
therapists conducting telemedicine assisted CBT. Second, with the exception of the initial
and post-treatment assessments and follow-ups, therapeutic or research staff has no face-to-
face contact with participants randomized to CBT4BN. By including the monthly telephone
check-ins with the study physician, we ensure some non-electronic contact with treatment
personnel; however, we monitor carefully whether any differences emerge in harms or
adverse events when face-to-face contact does not occur. Third, Internet access can be
unreliable. Patients experience outages, spotty wireless or slow connections, malfunctioning
computer hardware or are occasionally unable to find a private location to participate in the
chat therapy. These can all limit feasibility and acceptability of CBT4BN and are monitored
closely. Finally, participants also vary in how computer-savvy they are. More adept
participants find navigating the CBT4BN site and the chat room simple, whereas others are
challenged by the technology. Careful tracking of participant choice (i.e., which therapy
they hoped to be randomized to) as well as Internet efficacy will help inform for whom chat-
based therapy is most effective.
8. Conclusion
Results of this investigation may have public health significance and implications for
adaptation of evidence-based treatments for Internet delivery. First, by testing a novel
internet-based program, we will be able to determine the impact of Internet-based delivery
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on CBT specifically for BN and potentially open new avenues for broader and cost-effective
evidence-based mental health services for eating disorders. If non-inferiority is
demonstrated, there will be clear directions for additional research. For example, the
Internet-based program could be tested in a primary care setting in an effectiveness trial.
Finally, our research collaborative group will be interested in examining whether Internet-
based materials can augment clinic-based specialty care for the full range of eating
disorders.
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Appendix: Excerpt for Chat Therapy Session
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Table 2
Schedule of Topics for CBT4BN and CBTF2F
Week Topic
1 Introduction to CBT
2 The Language of CBT
3 Nutrition—The Basics
4 Challenging Automatic Thoughts
5 Alternatives to Binge Eating and Purging
6 Thought Restructuring




11 Relapse Prevention I
12 Relapse Prevention II
13 Complete Material—Flex Week
14 Complete Material—Flex Week
15 Review and Consolidate I
16 Review and Consolidate II
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